Tobira Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|
| Revenue | — | — | $832,000 | — |
| Operating income | −$52.9M | −$20.0M | −$15.2M | −$12.2M |
| Net income | −$7.0M | −$2.8M | −$18.6M | −$13.1M |
| Total assets | $65.5M | $8.3M | $45.8M | $21.8M |
| Total liabilities | $22.7M | $55.7M | $11.6M | $5.5M |
| Equity | $42.8M | −$109.4M | −$86.0M | −$69.0M |
| EPS (diluted) | — | — | — | — |
| Shares out. | 33.6M | 25.3M | 21.3M | 221,272 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- —
- Net margin
- —
- Return on equity
- −16.4%
- Return on assets
- −10.7%
- Return on capital (ROCE)
- −91.1%
- Liabilities / assets
- 34.7%
- Debt / equity
- 0.53×
- Book value / share
- $1.27
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- -5.99distress
- Accruals / assets
- 37.1%high accruals
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsNov 1, 2016
- Entered a material agreement · Director / officer change · Other material eventSep 20, 2016
- Results of operationsAug 9, 2016
- Other material eventJul 25, 2016
- Results of operationsMay 9, 2016
- Entered a material agreementApr 11, 2016
- Results of operationsMar 3, 2016
- Results of operationsNov 10, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2017
- SC 13G/AJan 18, 2017
- 15-12BFORM 15Nov 14, 2016
- EFFECTNov 9, 2016
- EFFECTNov 9, 2016
- SC 13D/ASCHEDULE 13D/A FOR TOBIRA THERAPEUTICS, INC. BY DOMAIN PARTNERS VI, L.P.Nov 4, 2016
- 4PRIMARY DOCUMENTNov 4, 2016
- 4PRIMARY DOCUMENTNov 3, 2016
- 4PRIMARY DOCUMENTNov 3, 2016
- 4PRIMARY DOCUMENTNov 3, 2016
- 4PRIMARY DOCUMENTNov 3, 2016
- 4PRIMARY DOCUMENTNov 3, 2016
- SC 13D/ANov 3, 2016
- S-8 POSNov 3, 2016
- S-8 POSNov 3, 2016
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.